|
2025-03-31 |
2025-03-28 |
PS
Planned sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
758
-12.5%
231.67
USD 175,606
|
758
-12.5%
|
231.67
|
USD 175,606
|
|
|
2025-03-31 |
2025-03-28 |
PS
Planned sale
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Officer
|
2,635
-34.7%
231.67
USD 610,450
|
2,635
-34.7%
|
231.67
|
USD 610,450
|
|
|
2025-03-07 |
2025-03-05 |
S
Sale
|
ANDERSON KERRII B
Non-Executive Director
|
500
-3.7%
255.63
USD 127,817
|
500
-3.7%
|
255.63
|
USD 127,817
|
|
|
2025-03-04 |
2025-02-28 |
PS
Planned sale
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Officer
|
5,339
-51.8%
249.23
USD 1,330,639
|
5,339
-51.8%
|
249.23
|
USD 1,330,639
|
|
|
2025-02-27 |
2025-02-25 |
S
Sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
1,314
-37.7%
251.30
USD 330,208
|
1,314
-37.7%
|
251.30
|
USD 330,208
|
|
|
2025-02-26 |
2025-02-24 |
PS
Planned sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
226
-4.7%
250.40
USD 56,590
|
226
-4.7%
|
250.40
|
USD 56,590
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
1,413
-41.5%
246.10
USD 347,739
|
1,413
-41.5%
|
246.10
|
USD 347,739
|
|
|
2025-02-13 |
2025-02-11 |
PS
Planned sale
|
Schechter Adam H
President & CEO
Executive Director
|
6,121
-6.6%
244.62
USD 1,497,319
|
6,121
-6.6%
|
244.62
|
USD 1,497,319
|
|
|
2025-01-08 |
2025-01-07 |
PS
Planned sale
|
ANDERSON KERRII B
Non-Executive Director
|
1,000
-7.3%
235.00
USD 235,000
|
1,000
-7.3%
|
235.00
|
USD 235,000
|
|
|
2024-12-04 |
2024-12-02 |
S
Sale
|
EISENBERG GLENN A
Executive Vice President
Officer
|
11,711
-27.2%
240.43
USD 2,815,651
|
11,711
-27.2%
|
240.43
|
USD 2,815,651
|
|
|
2024-12-04 |
2024-12-02 |
S
Sale
|
Gilliland Dwight Gary
Non-Executive Director
|
1,000
-11.5%
241.00
USD 241,000
|
1,000
-11.5%
|
241.00
|
USD 241,000
|
|
|
2024-11-26 |
2024-11-22 |
S
Sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
3,672
-46.0%
238.91
USD 877,142
|
3,672
-46.0%
|
238.91
|
USD 877,142
|
|
|
2024-11-25 |
2024-11-21 |
S
Sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
1,000
-27.2%
239.42
USD 239,419
|
1,000
-27.2%
|
239.42
|
USD 239,419
|
|
|
2024-11-13 |
2024-11-11 |
PS
Planned sale
|
Schechter Adam H
President & CEO
Executive Director
|
6,189
-6.6%
243.47
USD 1,506,836
|
6,189
-6.6%
|
243.47
|
USD 1,506,836
|
|
|
2024-10-25 |
2024-10-24 |
PS
Planned sale
|
ANDERSON KERRII B
Non-Executive Director
|
1,000
-6.8%
230.00
USD 230,000
|
1,000
-6.8%
|
230.00
|
USD 230,000
|
|
|
2024-08-21 |
2024-08-19 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
2,000
-35.3%
227.05
USD 454,100
|
2,000
-35.3%
|
227.05
|
USD 454,100
|
|
|
2024-08-19 |
2024-08-15 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
9,071
-22.5%
224.55
USD 2,036,882
|
9,071
-22.5%
|
224.55
|
USD 2,036,882
|
|
|
2024-08-19 |
2024-08-15 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
2,950
-6.8%
223.62
USD 659,670
|
2,950
-6.8%
|
223.62
|
USD 659,670
|
|
|
2024-08-19 |
2024-08-15 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
2,979
-6.4%
222.65
USD 663,273
|
2,979
-6.4%
|
222.65
|
USD 663,273
|
|
|
2024-08-09 |
2024-08-08 |
PS
Planned sale
|
ANDERSON KERRII B
Non-Executive Director
|
586
-3.8%
225.00
USD 131,850
|
586
-3.8%
|
225.00
|
USD 131,850
|
|
|
2024-08-09 |
2024-08-07 |
PS
Planned sale
|
ANDERSON KERRII B
Non-Executive Director
|
414
-2.6%
225.00
USD 93,150
|
414
-2.6%
|
225.00
|
USD 93,150
|
|
|
2024-08-07 |
2024-08-05 |
S
Sale
|
BERBERIAN LANCE
EVP, CIO & CTO
Officer
|
9,848
-38.2%
228.95
USD 2,254,685
|
9,848
-38.2%
|
228.95
|
USD 2,254,685
|
|
|
2024-08-07 |
2024-08-05 |
S
Sale
|
BERBERIAN LANCE
EVP, CIO & CTO
Officer
|
2,245
-8.0%
229.79
USD 515,867
|
2,245
-8.0%
|
229.79
|
USD 515,867
|
|
|
2024-05-16 |
2024-05-14 |
S
Sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
200
-3.4%
210.84
USD 42,167
|
200
-3.4%
|
210.84
|
USD 42,167
|
|
|
2024-05-16 |
2024-05-14 |
S
Sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
1,800
-23.6%
210.83
USD 379,488
|
1,800
-23.6%
|
210.83
|
USD 379,488
|
|
|
2024-05-02 |
2024-05-02 |
S
Sale
|
ANDERSON KERRII B
Non-Executive Director
|
250
-1.6%
200.10
USD 50,025
|
250
-1.6%
|
200.10
|
USD 50,025
|
|
|
2024-05-02 |
2024-04-30 |
S
Sale
|
ANDERSON KERRII B
Non-Executive Director
|
250
-1.5%
204.14
USD 51,034
|
250
-1.5%
|
204.14
|
USD 51,034
|
|
|
2024-05-01 |
2024-04-29 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
2,439
-53.9%
204.33
USD 498,358
|
2,439
-53.9%
|
204.33
|
USD 498,358
|
|
|
2024-04-03 |
2024-04-01 |
PS
Planned sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
3,500
-46.8%
217.29
USD 760,515
|
3,500
-46.8%
|
217.29
|
USD 760,515
|
|
|
2024-04-03 |
2024-04-01 |
PS
Planned sale
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Officer
|
6,477
-56.3%
217.29
USD 1,407,387
|
6,477
-56.3%
|
217.29
|
USD 1,407,387
|
|
|
2024-03-29 |
2024-03-28 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
3,553
-31.8%
216.74
USD 770,077
|
3,553
-31.8%
|
216.74
|
USD 770,077
|
|
|
2024-03-11 |
2024-03-07 |
PS
Planned sale
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Officer
|
5,048
-50.1%
218.45
USD 1,102,736
|
5,048
-50.1%
|
218.45
|
USD 1,102,736
|
|
|
2024-03-11 |
2024-03-07 |
PS
Planned sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
227
-5.6%
218.45
USD 49,588
|
227
-5.6%
|
218.45
|
USD 49,588
|
|
|
2024-02-22 |
2024-02-21 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
1,553
-6.2%
217.98
USD 338,529
|
1,553
-6.2%
|
217.98
|
USD 338,529
|
|
|
2024-02-22 |
2024-02-21 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
6,665
-21.0%
217.52
USD 1,449,774
|
6,665
-21.0%
|
217.52
|
USD 1,449,774
|
|
|
2024-02-22 |
2024-02-21 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
7,907
-19.9%
215.68
USD 1,705,349
|
7,907
-19.9%
|
215.68
|
USD 1,705,349
|
|
|
2024-02-22 |
2024-02-21 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
18,379
-31.6%
215.37
USD 3,958,214
|
18,379
-31.6%
|
215.37
|
USD 3,958,214
|
|
|
2024-02-22 |
2024-02-21 |
S
Sale
|
DiVincenzo Jonathan P.
EVP, Pres, Central Labs & Intl
Officer
|
500
-12.8%
215.49
USD 107,745
|
500
-12.8%
|
215.49
|
USD 107,745
|
|
|
2024-02-15 |
2024-02-13 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
237
-3.0%
226.45
USD 53,669
|
237
-3.0%
|
226.45
|
USD 53,669
|
|
|
2024-02-09 |
2024-02-08 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
259
-3.3%
222.06
USD 57,514
|
259
-3.3%
|
222.06
|
USD 57,514
|
|
|
2024-02-06 |
2024-02-05 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
193
-2.5%
220.57
USD 42,570
|
193
-2.5%
|
220.57
|
USD 42,570
|
|
|
2023-11-20 |
2023-11-16 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
1,384
-39.9%
210.71
USD 291,627
|
1,384
-39.9%
|
210.71
|
USD 291,627
|
|
|
2023-08-10 |
2023-08-08 |
S
Sale
|
ANDERSON KERRII B
Non-Executive Director
|
5,000
-24.7%
211.57
USD 1,057,833
|
5,000
-24.7%
|
211.57
|
USD 1,057,833
|
|
|
2023-07-03 |
2023-06-29 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
212
-2.7%
240.00
USD 50,880
|
212
-2.7%
|
240.00
|
USD 50,880
|
|
|
2023-05-23 |
2023-05-19 |
S
Sale
|
Kirchgraber Paul R
CEO, Covance Drug Development
Officer
|
4,300
-24.9%
216.91
USD 932,707
|
4,300
-24.9%
|
216.91
|
USD 932,707
|
|
|
2023-05-22 |
2023-05-18 |
PS
Planned sale
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Officer
|
1,500
-18.3%
216.77
USD 325,155
|
1,500
-18.3%
|
216.77
|
USD 325,155
|
|
|
2023-04-03 |
2023-03-31 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
3,897
-36.8%
225.81
USD 879,982
|
3,897
-36.8%
|
225.81
|
USD 879,982
|
|
|
2023-02-23 |
2023-02-21 |
S
Sale
|
Kirchgraber Paul R
CEO, Covance Drug Development
Officer
|
8,000
-46.9%
250.58
USD 2,004,675
|
8,000
-46.9%
|
250.58
|
USD 2,004,675
|
|
|
2023-02-16 |
2023-02-14 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
309
-4.4%
247.63
USD 76,518
|
309
-4.4%
|
247.63
|
USD 76,518
|
|
|
2023-02-09 |
2023-02-07 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
219
-3.9%
243.01
USD 53,219
|
219
-3.9%
|
243.01
|
USD 53,219
|
|
|
2023-02-09 |
2023-02-07 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
409
-5.8%
243.01
USD 99,391
|
409
-5.8%
|
243.01
|
USD 99,391
|
|
|
2023-02-06 |
2023-02-03 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
324
-4.6%
253.90
USD 82,264
|
324
-4.6%
|
253.90
|
USD 82,264
|
|
|
2023-02-06 |
2023-02-03 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
173
-3.1%
253.90
USD 43,925
|
173
-3.1%
|
253.90
|
USD 43,925
|
|
|
2022-11-10 |
2022-11-08 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
1,116
-14.3%
232.67
USD 259,660
|
1,116
-14.3%
|
232.67
|
USD 259,660
|
|
|
2022-09-28 |
2022-09-26 |
PS
Planned sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
2,830
-9.4%
211.86
USD 599,573
|
2,830
-9.4%
|
211.86
|
USD 599,573
|
|
|
2022-09-28 |
2022-09-26 |
PS
Planned sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
11,699
-28.1%
211.13
USD 2,470,064
|
11,699
-28.1%
|
211.13
|
USD 2,470,064
|
|
|
2022-09-28 |
2022-09-26 |
PS
Planned sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
4,844
-10.4%
210.21
USD 1,018,242
|
4,844
-10.4%
|
210.21
|
USD 1,018,242
|
|
|
2022-09-28 |
2022-09-26 |
PS
Planned sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
5,627
-10.8%
209.29
USD 1,177,697
|
5,627
-10.8%
|
209.29
|
USD 1,177,697
|
|
|
2022-09-13 |
2022-09-07 |
PP
Planned purchase
|
Caveney Brian J
EVP, President of Diagnostics
Officer
|
44
+0.3%
231.20
USD 10,251
|
44
+0.3%
|
231.20
|
USD 10,251
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
1,500
-2.8%
254.88
USD 382,319
|
1,500
-2.8%
|
254.88
|
USD 382,319
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
19,338
-26.5%
254.26
USD 4,916,861
|
19,338
-26.5%
|
254.26
|
USD 4,916,861
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Officer
|
11,262
-13.4%
253.27
USD 2,852,270
|
11,262
-13.4%
|
253.27
|
USD 2,852,270
|
|
|
2022-08-03 |
2022-08-01 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
10
-0.5%
258.71
USD 2,587
|
10
-0.5%
|
258.71
|
USD 2,587
|
|
|
2022-08-03 |
2022-08-01 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
757
-28.5%
258.60
USD 195,760
|
757
-28.5%
|
258.60
|
USD 195,760
|
|
|
2022-08-03 |
2022-08-01 |
S
Sale
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Officer
|
1,809
-48.9%
258.31
USD 467,287
|
1,809
-48.9%
|
258.31
|
USD 467,287
|
|
|
2022-06-14 |
2022-06-07 |
B
Purchase
|
Caveney Brian J
EVP, President of Diagnostics
Officer
|
42
+0.3%
242.19
USD 10,174
|
42
+0.3%
|
242.19
|
USD 10,174
|
|
|
2022-03-29 |
2022-03-25 |
PS
Planned sale
|
Williams R Sanders
Non-Executive Director
|
572
-8.2%
272.98
USD 156,145
|
572
-8.2%
|
272.98
|
USD 156,145
|
|
|
2022-03-14 |
2022-03-10 |
S
Sale
|
Summy Amy B.
EVP, Chief Marketing Officer
Officer
|
249
-49.9%
262.21
USD 65,290
|
249
-49.9%
|
262.21
|
USD 65,290
|
|
|
2022-02-18 |
2022-02-16 |
B
Purchase
|
NEUPERT PETER M
Non-Executive Director
|
600
+6.2%
264.57
USD 158,742
|
600
+6.2%
|
264.57
|
USD 158,742
|
|
|
2022-02-18 |
2022-02-16 |
B
Purchase
|
NEUPERT PETER M
Non-Executive Director
|
1,600
+19.9%
263.98
USD 422,368
|
1,600
+19.9%
|
263.98
|
USD 422,368
|
|
|
2022-02-18 |
2022-02-16 |
B
Purchase
|
NEUPERT PETER M
Non-Executive Director
|
1,300
+19.2%
262.85
USD 341,705
|
1,300
+19.2%
|
262.85
|
USD 341,705
|
|
|
2022-02-17 |
2022-02-15 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
207
-3.0%
273.98
USD 56,714
|
207
-3.0%
|
273.98
|
USD 56,714
|
|
|
2022-02-17 |
2022-02-15 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
207
-3.8%
273.98
USD 56,714
|
207
-3.8%
|
273.98
|
USD 56,714
|
|
|
2022-02-08 |
2022-02-07 |
PS
Planned sale
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Officer
|
204
-3.0%
277.38
USD 56,586
|
204
-3.0%
|
277.38
|
USD 56,586
|
|
|
2022-02-08 |
2022-02-07 |
PS
Planned sale
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Officer
|
218
-4.0%
277.38
USD 60,469
|
218
-4.0%
|
277.38
|
USD 60,469
|
|
